A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Phase 1
18+
5 sites in CA, NJ, TN +1
What this study is about
This Phase 1 study is focused on people with egfr. The primary outcome being measured is Evaluation of the safety and tolerability of EPI-326.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Evaluation of the safety and tolerability of EPI-326
Secondary: Determination of area under the concentration-time curve (AUC), Determination of clearance (CL) from the blood, Determination of maximum (Cmax) and minimum (Cmin) plasma concentration, Duration of response (DOR), Objective response rate (ORR)
Oncology, Respiratory